Blood Coagulation Tests: Laboratory tests for evaluating the individual's clotting mechanism.Blood Coagulation: The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.Partial Thromboplastin Time: The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.Thrombelastography: Use of a thrombelastograph, which provides a continuous graphic record of the physical shape of a clot during fibrin formation and subsequent lysis.Blood Coagulation Disorders: Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.Prothrombin Time: Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS.Blood Coagulation Factors: Endogenous substances, usually proteins, that are involved in the blood coagulation process.Disseminated Intravascular Coagulation: A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.Thrombin Time: Clotting time of PLASMA mixed with a THROMBIN solution. It is a measure of the conversion of FIBRINOGEN to FIBRIN, which is prolonged by AFIBRINOGENEMIA, abnormal fibrinogen, or the presence of inhibitory substances, e.g., fibrin-fibrinogen degradation products, or HEPARIN. BATROXOBIN, a thrombin-like enzyme unaffected by the presence of heparin, may be used in place of thrombin.Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.Hydroxyethyl Starch Derivatives: Starches that have been chemically modified so that a percentage of OH groups are substituted with 2-hydroxyethyl ether groups.Prothrombin: A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.Hemostatics: Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure.Lupus Coagulation Inhibitor: An antiphospholipid antibody found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications.Thrombin: An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN.Battered Child Syndrome: A clinical condition resulting from repeated physical and psychological injuries inflicted on a child by the parents or caregivers.Hemostasis: The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION.Blood Component Transfusion: The transfer of blood components such as erythrocytes, leukocytes, platelets, and plasma from a donor to a recipient or back to the donor. This process differs from the procedures undertaken in PLASMAPHERESIS and types of CYTAPHERESIS; (PLATELETPHERESIS and LEUKAPHERESIS) where, following the removal of plasma or the specific cell components, the remainder is transfused back to the donor.Phlebotomy: The techniques used to draw blood from a vein for diagnostic purposes or for treatment of certain blood disorders such as erythrocytosis, hemochromatosis, polycythemia vera, and porphyria cutanea tarda.Factor Xa: Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.Anticoagulants: Agents that prevent clotting.Factor VII: Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor VIIa in the extrinsic pathway of blood coagulation. The activated form then catalyzes the activation of factor X to factor Xa.Factor X: Storage-stable glycoprotein blood coagulation factor that can be activated to factor Xa by both the intrinsic and extrinsic pathways. A deficiency of factor X, sometimes called Stuart-Prower factor deficiency, may lead to a systemic coagulation disorder.Platelet Count: The number of PLATELETS per unit volume in a sample of venous BLOOD.Factor IX: Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease).Factor VIIa: Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation.Factor XIII: A fibrin-stabilizing plasma enzyme (TRANSGLUTAMINASES) that is activated by THROMBIN and CALCIUM to form FACTOR XIIIA. It is important for stabilizing the formation of the fibrin polymer (clot) which culminates the coagulation cascade.Plasma: The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION.Whole Blood Coagulation Time: The time required by whole blood to produce a visible clot.Heparin: A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.Factor XIa: Activated form of factor XI. In the intrinsic pathway, Factor XI is activated to XIa by factor XIIa in the presence of cofactor HMWK; (HIGH MOLECULAR WEIGHT KININOGEN). Factor XIa then activates factor IX to factor IXa in the presence of calcium.Factor VIII: Blood-coagulation factor VIII. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.Fibrinolysis: The natural enzymatic dissolution of FIBRIN.Blood Specimen Collection: The taking of a blood sample to determine its character as a whole, to identify levels of its component cells, chemicals, gases, or other constituents, to perform pathological examination, etc.Blood Cell Count: The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.Hemorrhage: Bleeding or escape of blood from a vessel.Blood Coagulation Factor Inhibitors: Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria.Coagulants: Agents that cause clotting.Antithrombin III: A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.Protein C: A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.Factor V: Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease.Factor IXa: Activated form of factor IX. This activation can take place via the intrinsic pathway by the action of factor XIa and calcium, or via the extrinsic pathway by the action of factor VIIa, thromboplastin, and calcium. Factor IXa serves to activate factor X to Xa by cleaving the arginyl-leucine peptide bond in factor X.Patient Access to Records: The freedom of patients to review their own medical, genetic, or other health-related records.Hematologic Diseases: Disorders of the blood and blood forming tissues.Occult Blood: Chemical, spectroscopic, or microscopic detection of extremely small amounts of blood.Anemia, Sickle Cell: A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.Problem-Based Learning: Instructional use of examples or cases to teach using problem-solving skills and critical thinking.Men's Health: The concept covering the physical and mental conditions of men.Pharmacy Service, Hospital: Hospital department responsible for the receiving, storing, and distribution of pharmaceutical supplies.Learning Curve: The course of learning of an individual or a group. It is a measure of performance plotted over time.Students, Pharmacy: Individuals enrolled in a school of pharmacy or a formal educational program leading to a degree in pharmacy.Gels: Colloids with a solid continuous phase and liquid as the dispersed phase; gels may be unstable when, due to temperature or other cause, the solid phase liquefies; the resulting colloid is called a sol.Menstruation Disturbances: Variations of menstruation which may be indicative of disease.Vaginal Creams, Foams, and Jellies: Medicated dosage forms for topical application in the vagina. A cream is a semisolid emulsion containing suspended or dissolved medication; a foam is a dispersion of a gas in a medicated liquid resulting in a light, frothy mass; a jelly is a colloidal semisolid mass of a water soluble medicated material, usually translucent.Hormone Replacement Therapy: Therapeutic use of hormones to alleviate the effects of hormone deficiency.Administration, Intravaginal: The insertion of drugs into the vagina to treat local infections, neoplasms, or to induce labor. The dosage forms may include medicated pessaries, irrigation fluids, and suppositories.Injections: Introduction of substances into the body using a needle and syringe.Mesial Movement of Teeth: Migration of the teeth toward the midline or forward in the DENTAL ARCH. (From Boucher's Clinical Dental Terminology, 4th ed)Estrogen Replacement Therapy: The use of hormonal agents with estrogen-like activity in postmenopausal or other estrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, DYSPAREUNIA, and progressive development of OSTEOPOROSIS. This may also include the use of progestational agents in combination therapy.Pyridones: Pyridine derivatives with one or more keto groups on the ring.ThiophenesBlood Banks: Centers for collecting, characterizing and storing human blood.Marketing: Activity involved in transfer of goods from producer to consumer or in the exchange of services.Directed Tissue Donation: Tissue, organ, or gamete donation intended for a designated recipient.Blood Preservation: The process by which blood or its components are kept viable outside of the organism from which they are derived (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism).ItalyPlatelet Aggregation Inhibitors: Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.Phenindione: An indandione that has been used as an anticoagulant. Phenindione has actions similar to WARFARIN, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.Persistent Vegetative State: Vegetative state refers to the neurocognitive status of individuals with severe brain damage, in whom physiologic functions (sleep-wake cycles, autonomic control, and breathing) persist, but awareness (including all cognitive function and emotion) is abolished.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Bacteriorhodopsins: Rhodopsins found in the PURPLE MEMBRANE of halophilic archaea such as HALOBACTERIUM HALOBIUM. Bacteriorhodopsins function as an energy transducers, converting light energy into electrochemical energy via PROTON PUMPS.Inventions: A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model.Intellectual Property: Property, such as patents, trademarks, and copyright, that results from creative effort. The Patent and Copyright Clause (Art. 1, Sec. 8, cl. 8) of the United States Constitution provides for promoting the progress of science and useful arts by securing for limited times to authors and inventors, the exclusive right to their respective writings and discoveries. (From Black's Law Dictionary, 5th ed, p1014)GermanyNational Institute of Allergy and Infectious Diseases (U.S.): Component of the NATIONAL INSTITUTES OF HEALTH. It conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. It was established in 1948.Oxymetholone: A synthetic hormone with anabolic and androgenic properties. It is used mainly in the treatment of anemias. According to the Fourth Annual Report on Carcinogens (NTP 85-002), this compound may reasonably be anticipated to be a carcinogen. (From Merck Index, 11th ed)Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.National Institute of General Medical Sciences (U.S.): Component of the NATIONAL INSTITUTES OF HEALTH. It conducts and supports basic biomedical research that is not targeted to specific diseases and funds studies on genes, proteins, and cells, as well as on fundamental processes like communication within and between cells and metabolism. It was established in 1962.Search Engine: Software used to locate data or information stored in machine-readable form locally or at a distance such as an INTERNET site.Monocytes, Activated Killer: Monocytes made cytotoxic by IN VITRO incubation with CYTOKINES, especially INTERFERON-GAMMA. The cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients.Fraud: Exploitation through misrepresentation of the facts or concealment of the purposes of the exploiter.Drug Costs: The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).Tuberculosis: Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM.Interferon-gamma: The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.Anaphylaxis: An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.Allergy and Immunology: A medical specialty concerned with the hypersensitivity of the individual to foreign substances and protection from the resultant infection or disorder.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.Publishing: "The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.Orthodontics: A dental specialty concerned with the prevention and correction of dental and oral anomalies (malocclusion).Sodium: A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23.Heparin, Low-Molecular-Weight: Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.Ubiquitin Thiolesterase: A thioester hydrolase which acts on esters formed between thiols such as DITHIOTHREITOL or GLUTATHIONE and the C-terminal glycine residue of UBIQUITIN.Ubiquitin-Specific Proteases: Members of the peptidase C19 family which regulate signal transduction by removing UBIQUITIN from specific protein substrates via a process known as deubiquitination or deubiquitylation.Alcohol Drinking: Behaviors associated with the ingesting of alcoholic beverages, including social drinking.Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.Blood Pressure: PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.Alcohols: Alkyl compounds containing a hydroxyl group. They are classified according to relation of the carbon atom: primary alcohols, R-CH2OH; secondary alcohols, R2-CHOH; tertiary alcohols, R3-COH. (From Grant & Hackh's Chemical Dictionary, 5th ed)Food: Any substances taken in by the body that provide nourishment.Cemeteries: Areas set apart as burial grounds.Office Automation: Use of computers or computer systems for doing routine clerical work, e.g., billing, records pertaining to the administration of the office, etc.Cats: The domestic cat, Felis catus, of the carnivore family FELIDAE, comprising over 30 different breeds. The domestic cat is descended primarily from the wild cat of Africa and extreme southwestern Asia. Though probably present in towns in Palestine as long ago as 7000 years, actual domestication occurred in Egypt about 4000 years ago. (From Walker's Mammals of the World, 6th ed, p801)Pets: Animals kept by humans for companionship and enjoyment, as opposed to DOMESTIC ANIMALS such as livestock or farm animals, which are kept for economic reasons.Surgery, Veterinary: A board-certified specialty of VETERINARY MEDICINE, requiring at least four years of special education, training, and practice of veterinary surgery after graduation from veterinary school. In the written, oral, and practical examinations candidates may choose either large or small animal surgery. (From AVMA Directory, 43d ed, p278)

Values of three coagulation screening tests of precolostral calves. (1/893)

Prothrombin times, partial thromboplastin times and platelet counts were performed to determine normal values and to screen for coagulation defects of precolostral calves. The precolostral calves were in two groups: one group of a few calves was tested two years before the second larger group. The results for both groups were similar. The tests were performed on postcolostral calves and on mature cows to compare their values with those of precolostral calves. The mean values of prothrombin times and partial thromboplastin times of precolostral calves in the first group were 18.8 seconds and 54.8 seconds respectively. The mean values of prothrombin times and partial thromboplastin times of precolostral calves in the second group were 18.8 seconds and 50.8 seconds respectively. The mean platelet count was 422,400/cmm for the first group and 482,800/cmm for the second group.  (+info)

Compound-heterozygous mutations in the plasminogen gene predispose to the development of ligneous conjunctivitis. (2/893)

Homozygous type I plasminogen deficiency has been identified as a cause of ligneous conjunctivitis. In this study, 5 additional patients with ligneous conjunctivitis are examined. Three unrelated patients (1 boy, 1 elderly woman, and 1 man) had plasminogen antigen levels of less than 0.4, less than 0.4, and 2.4 mg/dL, respectively, but had plasminogen functional residual activity of 17%, 18%, and 17%, respectively. These subjects were compound-heterozygotes for different missense mutations in the plasminogen gene: Lys19 --> Glu/Arg513 --> His, Lys19 --> Glu/Arg216 --> His, and Lys19 --> Glu/Leu128 --> Pro, respectively. The other 2 patients, a 14-year-old boy and his 19-year-old sister, who both presented with a severe course of the disease, exhibited plasminogen antigen and functional activity levels below the detection limit (<0.4 mg/dL and <5%, respectively). These subjects were compound-heterozygotes for a deletion mutation (del Lys212) and a splice site mutation in intron Q (Ex17 + 1del-g) in the plasminogen gene. These findings show that certain compound-heterozygous mutations in the plasminogen gene may be associated with ligneous conjunctivitis. Our findings also suggest that the severity of clinical symptoms of ligneous conjunctivitis and its associated complications may depend on the amount of plasminogen functional residual activity.  (+info)

Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. (3/893)

Polyethylene glycol (PEG)-hirudin is a derivative of hirudin with a long plasma half-life. We have compared the efficacy of PEG-hirudin with unfractionated heparin (UH) in preventing arterial thrombosis. Arterial thrombus formation was induced ex vivo in 12 healthy human volunteers by exposing a tissue factor-coated coverslip positioned in a parallel-plate perfusion chamber to flowing nonanticoagulated human blood drawn directly from an antecubital vein at an arterial wall shear rate of 2600 s-1 for 3.5 minutes. PEG-hirudin, UH, or saline (as control) were administered ex vivo through a heparin-coated mixing device positioned proximal to the perfusion chamber. Platelet and fibrin deposition was quantified by immunoenzymatic measure of the P-selectin and D-dimer content of dissolved plasmin-digested thrombi, respectively. UH was administered to a plasma concentration of 0.35 IU/mL. This concentration prolonged the activated partial thromboplastin time from 32+/-1 seconds to 79+/-4 seconds (P<0.01). UH did not significantly prevent platelet deposition. However, fibrin deposition was reduced by 39% (P<0.05). PEG-hirudin in plasma concentrations of 0.5, 2.5, and 5 microg/mL prolonged the activated partial thromboplastin time to 48+/-2, 87+/-4, and 118+/-4 seconds, respectively. In contrast to UH, PEG-hirudin prevented both platelet and fibrin deposition in a dose-dependent manner with a >80% reduction at 5 microg/mL (P<0.01). Furthermore, the plasma level of PEG-hirudin required to significantly prevent fibrin deposition (0.5 microg/mL) corresponded to a much shorter prolongation of activated partial thromboplastin time (48+/-2 seconds) than that needed for UH (79+/-4 seconds). Thus, our results are compatible with the view that thrombin is greatly involved in recruitment of platelets in evolving thrombi, and that PEG-hirudin is an effective agent for preventing arterial thrombosis in a human ex vivo experimental model.  (+info)

Abnormalities in liver function and coagulation profile following the Fontan procedure. (4/893)

OBJECTIVE: To investigate liver function and coagulation disorders in patients with a Fontan circulation at different time intervals after surgery. DESIGN: Retrospective analysis of clinical data and cross sectional study relating liver function and coagulation profile to time since surgery, in 28 surviving patients after the modified Fontan procedure. PATIENTS: 20 patients (71%) with atriopulmonary anastomosis, seven (25%) with atrioventricular anastomosis, and one (4%) with total cavopulmonary connection. Follow up ranged from 2.0 to 21.8 years (mean 11.1). RESULTS: Abnormal liver function tests, mainly reflecting cholestasis, were present in 21 patients who had a significantly longer follow up (p < 0.01). Protein synthesis was normal in almost all patients. Coagulation profile showed abnormalities in 22 patients. "Procoagulant" abnormalities-that is, decreased plasminogen and protein C activity-were found in 11 and five patients, respectively. The extent of these abnormalities was less in patients with a longer follow up. Anticoagulant abnormalities were factor V deficiency in 16 patients and factor VII deficiency in 17, resulting in a prolonged prothrombin time in 19 patients. Thirteen patients had both pro- and anticoagulant abnormalities. A prethrombotic state was present in five patients, with a significantly longer mean time interval since surgery (p = 0.05). Thus, although the individual procoagulant indices decreased with increasing time intervals since surgery, a prethrombotic state was found particularly in patients with a long term follow up. CONCLUSIONS: Mild cholestasis was mainly present in Fontan patients with a long duration of follow up. Along with laboratory procoagulant abnormalities indicating a prethrombotic state, anticoagulant abnormalities were also present. The coagulation profile varied at different time intervals after surgery. Thus detailed evaluation should be performed regularly, and the use of anticoagulants should be considered in every patient. Long term prospective studies are needed to evaluate the individual fluctuations of coagulation profile over time following a Fontan procedure.  (+info)

Comparative characterisation of Russell's viper (Daboia/Vipera russelli) venoms from different regions of the Indian peninsula. (5/893)

Russell's viper (Daboia/Vipera russelli) venom from different regions of India was subjected to chromatographic, electrophoretic, biochemical and immunological analysis. The elution profiles from ion-exchange chromatography and protein banding pattern from SDS-PAGE showed a significant variation in the constituents of venoms. The acidic proteins are found to be predominant in the venoms of eastern and western regions while basic proteins are the major contributors of the northern and southern regional venoms. The major variation of phospholipases A(2) in the venom samples of India may be described as: southern regional venom is rich in basic, toxic PLA(2) while this activity showed a dramatic decrease as one moves towards west, north and eastern regions of India. In addition, the caseinolytic, TAME-hydrolytic, anticoagulant, oedema-inducing and haemorrhagic activities of the venoms have also varied from one region to another. The muscle specimens of mice injected with venoms of different regions showed variable change in the muscle fibre damage and cell morphology. The eastern regional venom is most lethal among all the venoms. The lethal potencies for four regional venoms vary as: eastern>western>southern>northern. The polyclonal antibodies prepared against the venom of southern region showed cross-reaction with the venoms of other regions, but the extent of cross-reaction and diffusion patterns are different. However, the polyclonal antibodies prepared against southern regional venom showed no protection against lethal toxicity of other regional venoms.  (+info)

IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome. (6/893)

BACKGROUND AND OBJECTIVE: Autoantibodies to beta(2)-glycoprotein I (beta(2)-GPI) and/or prothrombin (FII) have been involved in the expression of lupus anticoagulant (LA) activity, an in vitro phenomenon associated with an increased risk of arterial and/or venous thromboembolic events. However, LA activity sustained by anti-FII antibodies has a much weaker association with thrombosis than LA activity sustained by anti-beta(2)-GPI antibodies. Because assays aimed at detecting LA activity are now commercially available, we evaluated the relative sensitivity to anti-FII and anti-beta(2)-GPI antibodies of a commercial LA assay in a consecutive series of patients with the clinical suspicion of anti-phospholipid antibody (APA) syndrome. DESIGN AND METHODS: One hundred and ten consecutive patients with the clinical suspicion of APA syndrome (primary in 39) and 36 healthy controls were evaluated for the presence of LA activity (LA, Staclot, Stago), anticardiolipin antibodies (Quanta Lite aCL IgG, IgM, Inova Diagnostics), and IgG binding to solid-phase and/or phospholipid (PL)-bound beta(2)-GPI and FII by ELISA assays developed an optimized in our laboratory. Odds ratios for the association of IgG binding activity with LA and the aCL IgG status were calculated. In LA patients, dependency of LA potency (as assessed by clotting time prolongation in absence or presence of hexagonal phospholipid) on autoantibody titers was analyzed by the generalized linear model. Total IgG fractions were purified from selected patients to evaluate their ability to inhibit prothrombin activation at low FII concentration. RESULTS: Anticardiolipin antibodies (aCL) of the IgG or IgM type were found in 64 and 23 patients and LA activity in 49 patients. Anti-beta(2)-GPI and anti-FII (solid-phase and PL-bound) IgG titers exceeding by more than 3 standard deviations the mean values observed in control subjects were found in 46 and 47 patients and in 56 and 30 patients respectively, with the highest titers detected in the subgroup of patients with both LA and aCL IgG. The relative risk of LA for patients free of anti-FII and/or anti-beta(2)-GPI IgG was 0.03 after stratification for the aCL IgG status. Anti-beta(2)-GPI (solid-phase and PL-bound) IgG (RR 34.4 and 12.6) and anti-FII (solid-phase) IgG (RR 6.33) were all associated with LA activity. However, when taking into account co-existence of anti-FII and anti-beta(2)-GPI IgG in the same patients, the relative risk of LA for patients with isolated anti-FII IgG (solid-phase and/or PL-bound) was 0.50, whereas it ranged from 4.24 to 8.70 for all the antibody combinations including anti-beta(2)-GPI IgG. Anti-beta(2)-GPI (PL-bound) and aCL IgG titers were the only significant predictors of LA potency determined in absence phospholipid (anti-beta(2)-GPI IgG) or in presence of hexagonal phospholipid (aCL IgG). Total IgG fractions purified from 12 patients (6 with anti-FII IgG) did not significantly inhibit factor II activity up to a 150-fold molar excess. INTERPRETATION AND CONCLUSIONS: These results highlight the high prevalence of anti-FII and anti-beta(2)-GPI IgG in patients with the clinical suspicion of APA syndrome and particularly in the subgroup of patients with LA activity. The fraction of LA activity which can be quenched by addition of hexagonal phospholipid is, however, only dependent on IgG directed to PL-bound beta(2)-GPI. Other antibodies associated with anticardiolipin IgG may explain residual clotting time prolongation observed in the presence of hexagonal phospholipid.  (+info)

Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults. (7/893)

BACKGROUND: Phylloquinone, found in dark-green vegetables and certain plant oils, is the primary dietary source of the fat-soluble vitamin K. Limited data suggest that the relative bioavailability of phylloquinone from vegetables is lower than that from a supplement. This finding is relevant to the maintenance of optimal vitamin K status. OBJECTIVE: The objective of this study was to compare, in younger and older adults, the relative bioavailability of phylloquinone from a vegetable with that of a fortified oil. DESIGN: In a crossover design with three 15-d residency periods in a metabolic unit, younger and older men and women (n = 36) consumed a mixed diet containing 100 microg phylloquinone/d. During 2 residency periods, the mixed diet was supplemented for 5 d with either broccoli (377 microg phylloquinone/d; broccoli diet) or phylloquinone-fortified oil (417 microg/d; oil diet). The relative bioavailability of phylloquinone was defined by the difference in plasma phylloquinone, percentage serum undercarboxylated osteocalcin (%ucOC), and urinary gamma-carboxyglutamic acid in response to 5 d of supplementation. RESULTS: For both younger and older adults, plasma phylloquinone concentrations were higher (P < 0.001) and %ucOC values were lower (P = 0.001) after the broccoli and oil diets than after the mixed diet only. Overall, the response to broccoli supplementation was not significantly different from the response to the fortified oil in either age group. Urinary gamma-carboxyglutamic acid did not change in response to supplementation. CONCLUSIONS: There was no significant difference in the relative bioavailability of phylloquinone, as evidenced by the lack of a significant difference in plasma phylloquinone and %ucOC between the 2 groups after either the broccoli or oil diets for younger and older adults.  (+info)

Laboratory evaluation of difenacoum as a rodenticide. (8/893)

The efficacy of difenacoum as a new anticoagulant rodenticide was evaluated by blood coagulation studies and laboratory feeding tests using warfarin-resistant and non-resistant common rats (Rattus norvegicus), ship rats (R. rattus) and house mice (Mus musculus). Prothrombin assays indicated that the compound had as marked an activity with warfarin-resistant common rats as coumatetralyl had with non-resistant animals. Feeding tests confirmed that 0-005% would be a near-optimal concentration for field use, although there was some evidence of unpalatability. Results with ship rats and house mice were less favourable. Trials with enclosed colonies of warfarin-resistant mice confirmed the laboratory finding that although difenacoum was more effective than all other currently used anticoagulants, it was unlikely to give complete control. It is concluded that difenacoum is a valuable new rodenticide, especiaaly for controlling warfarin-resistant common rats.  (+info)

*Watershed stroke

... and blood coagulation tests. The Oxfordshire Community Stroke Project classification (OCSP, also known as the Bamford or Oxford ... a disease of the blood vessels Arterial hypotension, or low blood pressure in the arteries Hypertension, or high blood pressure ... which can lead to deformed red blood cells clogging blood vessels and impeding blood flow Carotid artery stenosis, or narrowing ... Blood tests for risk factors also may be ordered, including cholesterol levels, triglyceride levels, homocysteine levels, ...

*Thromboelastography

... (TEG) is a method of testing the efficiency of blood coagulation. It is a test mainly used in surgery and ... More common tests of blood coagulation include prothrombin time (PT,INR) and partial thromboplastin time (aPTT) which measure ... The signal of the pin suspended in the blood sample is transmitted via an optical detector system. The test is started by ... The template below (Myeloid blood tests) is being considered for merging. See templates for discussion to help reach a ...

*Coagulation testing

Local tests characterize the results of work of the separate components of the blood coagulation system cascade, as well as of ... All the diversity of clinical tests of the blood coagulation system can be divided into 2 groups: global (integral, general) ... Blood clotting tests are the tests used for diagnostics of the hemostasis system. Coagulometer is the medical laboratory ... or prothrombin test, INR, PT) - velocity of passage of the extrinsic blood coagulation pathway poor plasma not sensitive to ...

*Factitious disorder imposed on self

... including complete blood count (CBC), urine toxicology, drug levels from blood, cultures, coagulation tests, assays for thyroid ... A summary of more common and reported cases of factitious disorder (Munchausen syndrome), and the laboratory tests used to ... In some cases CT scan, magnetic resonance imaging, psychological testing, electroencephalography, or electrocardiography may ...

*Aminocaproic acid

"Epsilon aminocaproic acid reduces blood transfusion and improves the coagulation test after pediatric open-heart surgery: a ... control of oral bleeding in patients with congenital and acquired coagulation disorders, control of perioperative bleeding ...

*Partial thromboplastin time

... is a medical test that characterizes blood coagulation, also known as clotting. A historical name for this measure is the ... The test is termed "partial" due to the absence of tissue factor from the reaction mixture. Blood is drawn into a test tube ... The template below (Myeloid blood tests) is being considered for merging. See templates for discussion to help reach a ... The blood is mixed, then centrifuged to separate blood cells from plasma (as Partial thromboplastin time is most commonly ...

*Vitamin K2

... a laboratory test measure of blood coagulation). Individuals taking anticoagulant medications, such as warfarin (coumarins), ... Blood. 104 (10): 3231-3232. doi:10.1182/blood-2004-04-1277. Koos, R.; Mahnken, A. H.; Mühlenbruch, G.; Brandenburg, V.; ... Vitamin K2 has only begun[when?] to be studied, and the few studies on humans suffer from either a small number of test ... Traditionally, K vitamins were recognized as the factor required for coagulation, but the functions performed by this vitamin ...

*Rotem

... test of blood-coagulation, see thromboelastography article Rotem Control & Management, advanced climate controllers and ...

*Winged infusion set

"Influence of the needle bore size on platelet count and routine coagulation testing". Blood Coagul Fibrinolysis. 17 (7): 557-61 ... butterflies based on belief that such small-bore needles hemolyze and/or clot blood samples and hence invalidate blood tests. ... When the needle enters the vein, venous blood pressure generally forces a small amount of blood into the set's transparent ... 25G butterflies connected directly to vacuum tubes caused the same amount of hemolysis and gave the same coagulation panel test ...

*Thrombophlebitis

Doppler ultrasound Extremity arteriography Blood coagulation studies (Blood clotting tests) Prevention consists of walking, ... Frequent checks of the pulse, blood pressure, and temperature may be required. If the cause is not readily identifiable, tests ... Thrombophlebitis causes include disorders related to increased tendency for blood clotting and reduced speed of blood in the ... doi:10.1182/blood-2006-10-053736. ISSN 0006-4971. PMC 1976377 . PMID 17496204. Retrieved 23 October 2016. Tamparo, Carol D. ( ...

*TCT

... a test used in blood coagulation Tocotrienol, a group of four isomers occurring in Vitamin E Trans Canada Trail, a proposed ...

*Nisoxetine

Doses ranging from 1 mg to 50 mg do not result in any changes in base line values in haematologic tests, routine blood ... chemistries, or coagulation parameters. Larger doses produce some side effects, but no electrocardiographic changes are ... Preclinical test conclude that the drug, in tested doses, appears to be safe for use in humans. Nisoxetine is a racemic ... Richard Kattau in the Rathbun laboratory tested the newly created drugs within the series of PPAs for their ability to reverse ...

*Gen-Probe

... analyzing blood transfusions for immune response, testing coagulation pathways, and organ transplant viability. Their products ... Gen-Probe was a company based in San Diego, California specializing in Clinical Diagnostics, Blood Screening, Transplant ... The Company's molecular diagnostics products were used for diagnosis of infectious diseases, blood screening, ... Lifesaving Benefits of Blood Screening Official website. ...

*Anticoagulant

Citrate is in liquid form in the tube and is used for coagulation tests, as well as in blood transfusion bags. It binds the ... In addition, test tubes used for laboratory blood tests will have chemicals added to stop blood clotting. Apart from heparin, ... Anticoagulants, commonly referred to as blood thinners, are chemical substances that prevent or reduce coagulation of blood, ... Vitamin E A Bethesda unit (BU) is a measure of blood coagulation inhibitor activity. It is the amount of inhibitor that will ...

*Test tube

... used to collect blood for coagulation and glucose-6-phosphate dehydrogenase testing. Small vials used in medicine may have a ... Test tube holder Test tube brush Microtiter plate MiniScience.com catalog: Test Tube, accessed March 27, 2009 M. Jeremy ... A chemistry test tube typically has a flat bottom, a round bottom, or a conical bottom. Some test tubes are made to accept a ... A test tube with a stopper is often used for temporary storage of chemical or biological samples. Culture tubes are test tubes ...

*List of MeSH codes (E01)

... blood coagulation tests MeSH E01.450.375.115.320 --- international normalized ratio MeSH E01.450.375.115.600 --- partial ... whole blood coagulation time MeSH E01.450.375.120 --- blood grouping and crossmatching MeSH E01.450.375.125 --- blood ... blood glucose self-monitoring MeSH E01.370.374.355 --- glucose tolerance test MeSH E01.370.374.530 --- ovarian function tests ... speech articulation tests MeSH E01.450.150.100 --- blood chemical analysis MeSH E01.450.150.100.100 --- blood gas analysis MeSH ...

*Gastrointestinal bleeding

Recommended laboratory blood testing includes: cross-matching blood, hemoglobin, hematocrit, platelets, coagulation time, and ... along with blood tests. Small amounts of bleeding may be detected by fecal occult blood test. Endoscopy of the lower and upper ... When there is significant blood loss over a short time, symptoms may include vomiting red blood, vomiting black blood, bloody ... This can be confirmed with a fecal occult blood test. Differentiating between upper and lower bleeding in some cases can be ...

*Reference ranges for blood tests

MedlinePlus Encyclopedia 003652 Antithrombin III at eMedicine Antithrombin CO000300 in Coagulation Test Handbook at ... and not venous which otherwise is standard for other blood tests. Acid-base and blood gases are among the few blood ... Reference ranges for blood tests are sets of values used by a health professional to interpret a set of medical test results ... are for total blood and not only blood plasma. These values are for total blood and not only blood plasma. Acute phase proteins ...

*Arterial blood gas test

Most syringes come pre-packaged and contain a small amount of heparin, to prevent coagulation. Other syringes may need to be ... The blood can also be drawn from an arterial catheter. An ABG test measures the blood-gas tension values of the arterial ... An ABG test can also measure the level of bicarbonate in the blood. Many blood-gas analyzers will also report concentrations of ... An arterial-blood gas (ABG) test measures the amounts of arterial gases, such as oxygen and carbon dioxide). An ABG test ...

*Factor X deficiency

In amyloidosis FX deficiency develops as FX and other coagulation factors are absorbed by amyloid fibrils. Blood tests are ... an enzyme protein that causes blood to clot in the coagulation cascade. Produced in the liver FX when activated cleaves ... While effective this treatment carries a risk of blood-borne viruses and fluid overload. If vitamin K levels are low, vitamin K ... Blood Tranfus. 14 (6): 585-586. doi:10.2450/2016.0335-15. PMC 5111391 . CS1 maint: Multiple names: authors list (link) M ...

*HELLP syndrome

In a woman with possible HELLP syndrome, a batch of blood tests is performed: a full blood count, a coagulation panel, liver ... The disseminated intravascular coagulation is treated with fresh frozen plasma to replenish the coagulation proteins, and the ... Disseminated intravascular coagulation is also seen in about 20% of all women with HELLP syndrome, and in 84% when HELLP is ... In one 1995 study, a positive D-dimer test in the presence of pre-eclampsia was reported to be predictive of woman who will ...

*Chester L. Sutula

... and tests to detect hepatitis, pregnancy and blood coagulation disorders. In 1981, with his wife, Jane, and a technology ... strip test) for urinalysis, blood chemistry, microbiology and quantitative, simple measurement of blood glucose for daily use ... These kits provided all of the components that were necessary to perform the test in a ready-to-use format, called PathoScreen ... 3/ In response to many requests, he formed Agdia Testing Services in 1982, a unit of Agdia. Agdia currently offers more than ...

*Thrombin time

It is used to diagnose blood coagulation disorders and to assess the effectiveness of fibrinolytic therapy. This test is ... is a blood test that measures the time it takes for a clot to form in the plasma of a blood sample containing anticoagulant, ... or under-filled in order to ensure the correct anticoagulant-to-blood ratio: one part anticoagulant per nine parts blood. The ... Whole blood is taken with either citrate or oxalate additive (if using the vacutainer system, this is a light blue top tube). ...

*Medical laboratory scientist

... renal function tests (RFT), thyroid function test (TFT), urinalysis, coagulation profile, lipid profile, blood type, semen ... They perform a full range of laboratory tests - from simple prenatal blood tests, to more complex tests to uncover diseases ... Common tests performed by Medical Laboratory Scientists are complete blood count (CBC), comprehensive metabolic panel (CMP), ... among general testing personnel and are usually qualified to perform the most complex clinical testing including HLA testing ( ...

*Thrombodynamics test

Thrombodynamics is a method for blood coagulation monitoring and anticoagulant control. This test is based on imitation of ... Thrombodynamics takes into account the spatial heterogeneity trombodinamiki processes in blood coagulation. The test is ... of blood coagulation initiated by localized coagulation activator under conditions similar to the conditions of the blood ... The template below (Myeloid blood tests) is being considered for merging. See templates for discussion to help reach a ...

*Haemophilia A

... these signs may lead to blood tests which indicates haemophilia. In other people, especially those with moderate or mild ... while digestive tract and cerebral haemorrhages are also germane to other coagulation disorders.Though typically not life- ... Joint damage is not a result of blood in the capsule but rather the healing process. When blood in the joint is broken down by ...
Factor Assays - Shop online with us for Factor Assays and other Chemistry Reagents, Controls and Consumables. Get Factor Assays at great rate.
Learn about the veterinary topic of Coagulation Tests in Hepatic Disease in Small Animals. Find specific details on this topic and related topics from the Merck Vet Manual.
A-FACT is an abnormal factor assay control designed to assess the sensitivity of the lower section of the standard curve. Lot specific assigned assay values for a wide variety of tests are included with each shipment. Published assay values include PT, APTT, Thrombin Time, Fibrinogen (Clauss) , Fibrinogen Antigen, Factors II, V, VII, VIII, IX, X, XI, XII, ATIII Antigen, ATIII Activity, vWF:Antigen, vWF:Activity, Protein C Antigen, Protein C Functional, Protein S Functional, Protein S Antigen and Plasminogen. This product is registered with the FDA as an in vitro diagnostic product and can be used without limitations.. Product URL : http://kingbiomed.com/products/a-fact-abnormal- ...
Tests: PT, aPTT, Fibrinogen, Thrombin Clotting Time, Factor Assays. Sample Size: 50 -L, 100 -L, 200 -L. Optics System: Constant current LED photo optic detection. Channels: 4 Temperature Control: 37-C - 0.5-C. Special Features: Stores standard curves; calculates final results for fibrinogens and factor assays. Calculates INRs and aPTT ratios. On-screen prompts for test instructions. LIS interfacing. Quality Control Features: Calculates mean, SD, and CV. Plots Levy-Jennings charts. Display: Fluorescent LCD. 6 lines x 40 characters. Printer: Accommodates 4 1/2 thermal paper. Reports include date, time, INR, average, technician and patient ID. Prints QC and standard curves. Power Requirements: 110/220 Vac, 50/60 Hz, 100 Watts max. Operating Environment: Room temperature. Dimensions: 8 1/2 H x 14 W x 14 D (22 cm H x 35 cm W x 33 cm D). Weight: 21 lbs. (9.5 kg).. ...
It offers both global as well as speciality coagulation tests, a fully automated coagulation analyzer the Ceveron® alpha and the new semi-automated analyzers the Ceveron® one, four and ten. The Ceveron® alpha TGA offers the unique feature of a fully automated thrombin generation measurement in the routine: CV ...
Dr. Kavita Chandak discusses snake remedies in relation to coagulopathies. - Snake Remedies - Boon for Coagulopathies - Homeopathy Papers
PubMed journal article Correlation of plasma coagulation tests and fibrinogenClauss with rotational thromboelastometry parameters and prediction of bleeding in dog were found in PRIME PubMed. Download Prime PubMed App to iPhone, iPad, or Android
Dilute Russell Viper Venom Time (dRVVT), Anti-Cardiolipin Ab, ACA, IgG, Anti ... Factor I (Fibrinogen), II, V, VII, VWF, VIII, IX, X, Urea solubility test, ... – A free PowerPoint PPT presentation (displayed as a Flash slide show) on PowerShow.com - id: 771cb-NTU2N
2016-2020 World Factor Assays Testing Market: Ambulatory Centers, Commercial Labs, Hospitals, Physician Offices, POC/Point-of-Care Locations-Competitive Landscape, Country Segment Forecasts, Innovative Technologies, Instrumentation Review Published by VPGMarketResearch.com at researchbeam.com 295 Pages
Dr. Tormey has several diverse research interests within the fields of Transfusion Medicine & Laboratory Hematology ranging from large clinical studies to translational research projects. Areas of current investigation include blood bank-based immunohematology where the properties of red blood cell alloantibodies in veteran populations are examined, particularly those factors influencing the duration of humoral response following alloimmunization. In addition, Dr. Tormey is interested in studying the biochemical and immunologic effects of storage on platelet components in the blood bank. Finally, he is also interested in studying coagulation assays, in particular the clinical scenarios leading to discrepant coagulation test results and the general impact of coagulation assays on transfusion-related care.. ...
APTT Si L Plus contains phospholipid extract and a near-colloidal particle activator. It is for use in the determination of Activated Partial Thromboplastin Times (aPTT) with sensitivity to lupus-like inhibitors, related coagulation factor assays, pre-surgical screening and monitoring of Heparin therapy using citrated plasma. The reagent can be used on manual, semi- automated and automated methods.. ...
AccessGUDID - ROTEM® (04260160470020)- The ROTEM® delta is designed for in-vitro diagnostic use by professionals in a laboratory environment. The ROTEM® delta is intended to be used to provide a qualitative and quantitative indication of the coagulation state of a blood sample. For this purpose the ROTEM® delta records the clot firmness changes in a sample of citrated whole blood as the sample clots, retracts and lyses in real time. The analyzer output consists of a qualitative graphical representation (mirrored coagulation curve - clot firmness over time) and several defined numerical parameters describing the curve quantitatively.
The BFT™ II Analyzer combines the advantages of mechanical and photo-optical clot-detecting principles by employing a unique turbodensitometric detection device. The semi-automated, dual-channel coagulometer is ideal for low-volume laboratories performing routine coagulation tests.
The BFT™ II Analyzer combines the advantages of mechanical and photo-optical clot-detecting principles by employing a unique turbodensitometric detection device. The semi-automated, dual-channel coagulometer is ideal for low-volume laboratories performing routine coagulation tests.
Complete report $6,100. DataPack (test volumes, sales forecasts, supplier shares) $3,950.. Summary. This comprehensive report contains 400 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the Spanish coagulation testing market during the next five years. The report explores business and technological trends in the Spanish coagulation testing market; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.. Coagulation Tests. Activated Clotting Time (ACT) (1), Activated Protein C Resistance ...
This comprehensive five-country report contains 500 pages, 120 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the European coagulation testing market during the next five years. The report explores business and technological trends in France, Germany, Italy, Spain, and the UK; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.. Coagulation Tests. Activated Clotting Time (ACT) (1), Activated Protein C Resistance ...
The Sysmex® CA-1500 System, with optional cap-piercing, is ideal for mid-volume laboratories requiring an easy to use analyzer capable of running clotting, chromogenic, and immunologic assays simultaneously. The system features multiple dilution analysis (MDA) for detecting inhibitors during factor assay analysis and accurate sample identification. By offering true 15-parameter random access testing and walk-away capability, the system offers both efficiency and flexibility for your laboratory.. ...
Background: The concept of developmental hemostasis has been universally accepted. Physiological reference ranges for coagulation tests are available for infants and children of different ages. However, on Oriental children they are rare.. Methods: Results of preoperative activated partial thromboplastin time (APTT) in neonates, infants, children aged 1-18 years and adults with minor elective surgery in a university affiliated hospital were reviewed retrospectively. Plasma activity of factors VIII, IX, XI, XII (FVIII: C, FIX: C, FXI: C, FXII: C) and lupus anticoagulants (LAC) in 47 children with prolonged APTT and 34 adult controls were measured to investigate the causes of prolongation.. Results: Compared with adults, APTT values were prolonged significantly and were age-dependent in children, especially in neonates and infants aged 1-6 months. Mean values for FXII: C and FIX: C in children with prolonged APTT values were significantly lower than those in adults ( ...
Thromboelastography (TEG) is a point-of-care whole blood coagulation monitor which provides information on specific aspects of coagulation including time to production of initial fibrin strands (R-time), time to develop clot (R-time, K-time), rate of fibrin build-up and cross linking (-angle), maximum clot strength (maximum amplitude bMA) and measures of fibrinolysis (decreasing amplitude post-MA). Abnormal TEG data may predict patients who will bleed. Spiess [2] found that TEG correlated well with ACT and coagulation profiles and whilst no coagulation test was consistently abnormal the TEG was the most accurate predictor of bleeding. Ereth studied a Platelet-activated clotting test (PACT HemoSTATUS), ACT and clotting studies, and TEG. Whilst PACT sensitivity and specificity was comparable to conventional coagulation tests in predicting blood loss, TEG was more predictive at both blood loss levels. Essell found that whilst the bleeding time and platelet count had sensitivities similar to the ...
Use this page to view the contact information, documents, and history of considerations for the coding analysis for labs (cal) for partial thromboplastin time (addition of icd-9-cm 289.81, primary hypercoagulable state as a covered indication) (cag-00327n).
Click the title to purchase the article.. Background:. "Viscoelastic tests (VETs) such as thromboelastography, rotational thromboelastography, and the Sonoclot Analyzer assess the entire process of clot formation through dissolution in real-time, and may provide additional therapeutic value to conventional laboratory coagulation tests. With the ability to obtain rapid results and identify specific coagulopathies, VETs has been examined in a variety of clinical scenarios, including cardiac surgery, trauma, obstetric emergencies, and liver transplant. Conclusion: This review provides a summary of clinical trials utilizing VETs in the aforementioned clinical scenarios, and suggests that VETs have demonstrated a capability to identify coagulopathies, utility in guiding algorithms to reduce the amount of transfusions, and a limited ability to predict bleeding events or mortality."1. ...
Thromboelastometry (TEM), previously named rotational thromboelastography (ROTEG) or rotational thromboelastometry (ROTEM), is an established viscoelastic method for hemostasis testing in whole blood. It is a modification of traditional thromboelastography (TEG). TEM investigates the interaction of coagulation factors, their inhibitors, anticoagulant drugs, blood cells, specifically platelets, during clotting and subsequent fibrinolysis. The rheological conditions mimic the sluggish flow of blood in veins. TEM is performed with the ROTEM whole blood analyzer (Tem Innovations GmbH, Munich) and is an enhancement of thrombelastography, originally described by H. Hartert in 1948. While traditional thromboelastography is a global assay for blood clotting disorders and drug effects, TEM is primarily used in combination with appropriate differential assays. They allow testing in the presence of therapeutic heparin concentrations and provide differential diagnostic information to support decisions in ...
A partial thromboplastin time (PTT) test measures how long it takes for a clot to form in a blood sample. A clot is a thick lump of blood that the body produces to seal leaks, wounds, cuts, and scratches and prevent excessive bleeding.. The bloods ability to clot involves platelets (also called thrombocytes) and proteins called clotting factors. Platelets are oval-shaped cells made in the bone marrow. Most clotting factors are made in the liver.. When a blood vessel breaks, platelets are first to the area to help seal off the leak and temporarily stop or slow the bleeding. But for the clot to become strong and stable, the action of clotting factors is required.. The bodys clotting factors are numbered using the Roman numerals I through XII. They work together in a specialized sequence, almost like pieces of a puzzle. When the last piece is in place, the clot develops - but if even one piece is missing or defective, the clot cant form.. The PTT test is used to evaluate the ability of a ...
Simultaneous or sequential haemorrhage and thrombosis in the presence of a prolonged activated partial thromboplastin time (aPTT) is a rare occurrence: we describe the case a 37 year old lady who developed post-delivery deep vein thrombosis treated w
Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: Results of gusto-i ...
A partial thromboplastin time (PTT) test is used to evaluate bloods ability to clot. It may be done as part of an evaluation for a bleeding disorder or to monitor the effects of blood-thinning medicine.
A partial thromboplastin time (PTT) test is used to evaluate bloods ability to clot. It may be done as part of an evaluation for a bleeding disorder or to monitor the effects of blood-thinning medicine.
A portable device for performing coagulation tests on a patients blood. Blood is first drawn from a patient using a lancet. The blood is then supplied to a disposable cuvette placed within the testing device. The blood is drawn into multiple conduits within the cuvette. Each of the conduits contains a dried or lyophilized activation reagent that is rehydrated by the blood. The blood in each of the conduits is then reciprocally moved across a restricted region until a predetermined degree of coagulation occurs. Since the coagulation time is being monitored in multiple conduits, a representation coagulation time for a given sample can be determined. In at least one of the conduits a normalizing control agent is present. The normalizing control agent counteracts any effects of anticoagulants present in the blood sample, thereby allowing the blood sample to have generally normal coagulation characteristics. The normalized blood is tested simultaneously with the untreated blood to provide a reference value
... ,The HEMOCHRON Response is a whole blood coagulation monitoring instrument designed to be used at the point-of-care. The Response includes an easy-to-read screen and data management features, including patient and operator ID options. QC and operator lockout can be enabled for enhanced regulatory co,medicine,medical supply,medical supplies,medical product
Synonyms for activated clotting time test in Free Thesaurus. Antonyms for activated clotting time test. 238 synonyms for act: do something, perform, move, function, go about, conduct yourself, undertake something, behave, react, go about, acquit yourself.... What are synonyms for activated clotting time test?
List of 9 causes of Partial thromboplastin time with kaolin (Kaolin cephalin clotting time), patient stories, diagnosis questions, and associated symptoms.
... |br|Hemochron Directcheck|br| Prothrombin Time Test (PT) |br| Normal 15 Vials |br| Accriva Diagnostics DCJPT-N Coagulation Control Hemochron Directcheck Prothrombin Time Test (PT) Normal 15 Vials Accriva Diagnostics DCJPT-N DCJPT-N Coagulation Control
This new manual coagulation analyzer is an opto-mechanical coagulation analyzer which applies the turbodensitometric measuring principle. This measuring principle is especially suited for lipemic and/or icteric colored samples. All routine coagulometric clotting tests such as Prothrombin Time, activated and partial Thromboplastin Time, Fibrinogen, and single Factor assays can be performed with CoaDATA 501. Results printed via external printer (optional) or can be read from the display ...
1] A new two-dimensional aerosol bin scheme, which resolves both aerosol size and black carbon (BC) mixing state for BC aging processes (e.g., condensation and coagulation) with 12 size × 10 mixing state bins, has been developed and implemented into the WRF-chem model (MS-resolved WRF-chem). The mixing state of BC simulated by this model is compared with direct measurements over the East Asian region in spring 2009. Model simulations generally reproduce the observed features of the BC mixing state, such as the size-dependent number fractions of BC-containing and BC-free particles and the coating thickness of BC-containing particles. This result shows that the model can simulate realistic BC mixing states in the atmosphere if condensation and coagulation processes are calculated explicitly with the detailed treatment of BC mixing state. Sensitivity simulations show that the condensation process is dominant for the growth of thinly coated BC particles, while the coagulation process is necessary ...
MAC54 Coagulometer Test Method: Dispersion light nephelometric analysis Test Principle: The highest point on first order differentiation, Percentage analysis
SummaryData concerning the presence of thromboplastin factors in dog erythrocytes are presented. The presence of these factors was judged by the influence of water hemolyzate of washed crythrocytes on the time of recalcification of the oxalated plasma and on utilization of prothrombin ...
Platelets and Coagulation Tests - Pathophysiology VideoPerhaps as a little kid you saw the animated movie Anastasia. It was a ... And with that lowdown on the coagulation cascade out of the way, its time we look at ... ...
... : ROTEM parameters of Extrinsically Activated Thromboelastometry test (EXTEM), Intrinsically Activated Thromboelastometry test (INTEM) and Fibrinogen Thromboelastometry test (FIBTEM) with normal reference range in a normal volunteer preoperatively [9 ...
ReportsnReports.com adds report 2014 Strategies for the Italian Hemostasis Diagnostic Testing Market to its store. This comprehensive report contains 402 pages, 35 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the Italian coagulation testing market during the next five years.. Complete report is available at http://www.reportsnreports.com/reports/274215-2014-strategies-for-the-italian-hemostasis-diagnostic-testing-market.html. The report explores business and technological trends in the Italian coagulation testing market; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.. Coagulation Tests. Activated Clotting Time (ACT) (1), Activated Protein C Resistance, ...
For rapid whole blood testing from the Cardiovascular Operating Room to the Cardiac Catherization Lab, Hemochron Signature Elite system standardizes ACT+, ACT-LR, PT and APTT testing at the point-of-care.
bs0630 portable blood electro coagulation machine price, blood coagulation analyzer or machine automated, roche coaguchek system coagulation analyzers, best price automated single channel boold coagulation, china yste502 fully automatic blood coagulation machine
MLT 2050 Clinical Hematology Credits 4 Goal Areas n/a View Course Outline The course will include development, normal and abnormal characteristics of the cellular elements of the blood; the basic techniques and instrumentation utilized in the hematology laboratory; the theory and techniques of coagulation studies; and the clinical correlation of all procedures. This course will include development, normal and abnormal characteristics of the cellular elements of blood; the basic techniques and instrumentation utilized in the hematology laboratory; the theory and techniques of coagulation studies; and the clinical correlation of all procedures. Prerequisite: Admission to the MLT Program MLT 1000, 1100 and 1200 ...
Experiencing unusual weight gain? Test for hormone imbalance, vitamin D and thyroid deficiency with HealthConfirm Lab home weight management test kit and get it shipped for free!
Activation of local and systemic coagulation processes are induced by several renal diseases and may require specific anticoagulation therapy. The first parts of this chapter are devoted to these...
DIC or disseminated intravascular coagulation is the problem with blood clots. DIC is really a significant situation that can induce long term organ harm and even death.
Blood vessel contraction, platelet activation and formation, and activation of coagulation factors, and their use in diagnosing coagulation defects and monitoring anticoagulant therapy. This course has a fee that is non-refundable once the term begins.
Online Doctor Chat - Irregular menstrunal cycles and time/tests for pregnancy Online doctor patient chat conversation by Dr. Raju A.T
After a more thorough reading and research to better understand this subject, I added excerpts and package them in such a way that readers would readily undestand and find answers to their curiosity. First of all I will start by describing the role of vit K in the coagulation process. Second, I will discuss why…
This test clocks the amount of time it takes for your blood to form a clot. You may need this test if your healthcare provider suspects that you have a bleeding disorder.
This condition is associated with many illnesses, particularly in those patients who are very ill like those individuals in an Intensive Care Unit. Stress may also activate clotting factors. DIC is diagnosed with blood tests which are analyzed to count the number of platelets as well as clotting factors. When a patient does have excessive bleeding and he/she is at any risk of DIC, physicians try to act quickly. ...
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
Your account has been temporarily locked Your account has been temporarily locked due to incorrect sign in attempts and will be automatically unlocked in 30 mins. For immediate assistance, contact Customer Service: 800-638-3030 (within USA), 301-223-2300 (international) [email protected] ...
Your account has been temporarily locked Your account has been temporarily locked due to incorrect sign in attempts and will be automatically unlocked in 30 mins. For immediate assistance, contact Customer Service: 800-638-3030 (within USA), 301-223-2300 (international) [email protected] ...
[106 Pages Report] Check for Discount on Global Automated Coagulation Analyzer Market Professional Survey Report 2016 report by QYResearch Group. This report Mainly covers the following product types The segment...
Create healthcare diagrams like this example called Coagulation in minutes with SmartDraw. SmartDraw includes 1000s of professional healthcare and anatomy chart templates that you can modify and make your own.
DIC labs are laboratory tests indicating the presence of disseminated intravascular coagulation, which is seen in up to 1 percent of hospital patients, according to Medscape. The condition is most...
Looking for online definition of activated partial thromboplastin time in the Medical Dictionary? activated partial thromboplastin time explanation free. What is activated partial thromboplastin time? Meaning of activated partial thromboplastin time medical term. What does activated partial thromboplastin time mean?
Definition of factor VIII activity in the Financial Dictionary - by Free online English dictionary and encyclopedia. What is factor VIII activity? Meaning of factor VIII activity as a finance term. What does factor VIII activity mean in finance?
TY - JOUR. T1 - The unwarranted use of replicate analysis in routine coagulation studies. AU - Sage-El, A.. AU - Burns, E.. AU - Wenz, B.. PY - 1985/1/1. Y1 - 1985/1/1. N2 - The need to assure the validity of semiautomated coagulation procedures by performing replicate determinations is assessed. Prothrombin times (PT) and activated partial thromboplastin times (aPTT) were run as duplicate assays using two different photo-optical detection systems. Sixty specimens with a broad range of PT and aPTT results were studied as aliquots of 80, 100, and 140 μL of plasma. A total of 1,440 studies were performed. No statistically significant differences were found among the data for complementary groups of assays. It is concluded that replicate analyses do not enhance the precision nor the accuracy of these coagulation studies. These factors are more controlled adequately by quality assurance procedures, including frequent calibration checks, the use of internal standards, and multilevel commercial ...
Introduction: The most commonly used test for monitoring heparin therapy is the activated partial thromboplastin time (aPTT). The response of available aPTT reagents to heparin varies significantly. The aim of this study was to highlight the differences between aPTT reagents stored in a dried format to select the most suitable formulations to be used for the development of point-of-care diagnostic devices used for monitoring of unfractionated heparin dose response. Methods: Ten reagents were analysed in terms of their performance in liquid and in dried form after storage for 24 h and 14 days. Performance was assessed by measurement of the clotting time (CT) as evidenced by the onset of thrombin formation using a chromogenic thrombin substrate in plasma samples activated with these formulations. Results: Reagents in all of the three forms tested (liquid, 24 h and 14 days) resulted in significant shortening of CTs in comparison with the nonactivated plasma CT. Liquids returned more rapid CTs in comparison
Use this page to view the contact information, documents, and history of considerations for the coding analysis for labs (cal) for prothrombin time and partial thromboplastin time (revision of icd-9-cm codes for swelling of limb) (cag-00201n).
This study investigated the effect of dabigatran on the activated partial thromboplastin time and activated clotting time in artrial fibrillation patients.
This study describes a novel microplate assay that measures FV coagulation activity during fibrin clot formation in human plasma which...
OBJECTIVE: To evaluate the efficacy and safety of fondaparinux compared with nadroparin for prevention of venous thromboembolism after arthroplasty. PATIENTS AND METHODS: One hundred fifteen patients were randomized into 2 treatment groups. Patients were given fondaparinux in Group I and nadroparin in Group II. Measurements were performed on Days 1, 5, and 21. The wound area was assessed with a subjective visual analog scale. RESULTS: The blood counts, clinical biochemical tests, and coagulation tests (ie, thrombin time, partial thromboplastin time, activated partial thromboplastin time, fibrinogen, prothrombin time-International Normalized Ratio, and antithrombin III activity) did not show statistically significant differences between Group I and Group II ...
A factor VIII activity blood test lets doctors evaluate the functioning of a protein that helps blood to clot. A clot is a lump of blood that the body produces to prevent excessive bleeding by sealing leaks from blood vessels caused by wounds, cuts, scratches, or other conditions.. Blood clotting is a process involving platelets (also called thrombocytes) and proteins called clotting factors. Platelets are oval-shaped cells made in the bone marrow. Most clotting factors are made in the liver. When a blood vessel breaks, platelets are first to the area to help seal the leak and temporarily stop or slow bleeding. But for the clot to become strong and stable, the action of clotting factors is required.. The bodys clotting factors are numbered using the Roman numerals I through XII. They work together in a specialized sequence, almost like pieces of a puzzle. When the last piece is in place, the clot develops - but if even one piece is missing or defective, the puzzle cant come together.. Factor ...
ReportsnReports.com adds report 2014 Strategies for the UK Coagulation Testing Market to its store. This comprehensive report contains 409 pages, 35 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the UK coagulation testing market during the next five years.. The report explores business and technological trends in the UK coagulation testing market; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.. Coagulation Tests. Activated Clotting Time (ACT) (1), Activated Protein C Resistance, Activated PTT (APTT), Alpha 2-Antiplasmin, Antithrombin III, Bleeding Time, D-Dimer, Factor II, Factor V, Factor V Leiden, Factor VII, Factor VIII, Factor IX, Factor Ixa, Factor X ...
Evidence exists that C is involved in the coagulation process (Zimmerman et al., J. Exp. Med., No. 6, 1971). It has been reported that C3 (β1C/β1A) is significantly depressed in most patients with DIC (Tomar et al., Thromb. Diath. Haemorrh., 3: 27, 1972). In the present study C3 and C4 were quantitated by single radial immunodiffusion in the plasma of patients suffering mostly from severe septic and traumatic conditions with and without shock. Examinations including detailed coagulation studies were performed on 30 selected patients and 14 showed characteristic signs of DIC. C3 was markedly diminished in 13, C4 in 9 of the 14 DIC patients. In patients with septicemia but without DIC, a larger variation of results was found. In this group, depressions of C3 were observed in 6, and of C4 in 3 of 10 cases and seemed to occur more frequently when the condition was complicated by shock.. ...
APTTP : Monitoring heparin therapy (unfractionated heparin)   Screening for certain coagulation factor deficiencies   Detection of coagulation inhibitors such as lupus anticoagulant, specific factor inhibitors, and nonspecific inhibitors
Complete a form to schedule an appointment with a licensed UnitedHealthcare® insurance agent to discuss a Medicare Advantage plan that may be right for you.
Measure disease-associated rat cytokines, chemokines, and growth factors using magnetic bead-based assays. Custom or premixed assay formats; low sample volumes.
Detect disease-associated mouse cytokines, chemokines, and growth factors with magnetic bead-based assays. Custom or premixed assay formats; low sample volumes.
See Coagulation Studies in Special Instructions.. Specimen Type: Platelet-poor plasma. Collection Container/Tube: Light-blue top (citrate). Submission Container/Tube: Polypropylene vial. Specimen Volume: 1 mL. Collection Instructions:. 1. Spin down, remove plasma. 2. Spin plasma again; remove plasma aliquot without disturbing bottom 0.5 mL. 3. Freeze specimen aliquot immediately at or below -40° C, if possible but no longer than 4 hours after collection. Additional Information:. 1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.. 2. If priority specimen, mark request form, give reason, and request a call-back.. 3. Each coagulation assay requested should have its own vial.. ...
We are leading supplier of Rotor,Cuvette,Analyzer,Coagulometer,Disposable,Test tubes,Gauge,IV sets,AXIM Abbott reagent,ELECSYS 2010 ROCHE Reagents,IMMULITE SIEMENS Reagents,Colorimetric cup,Disposable instrument, enjoy best price and best buy at Antonio Serio Prodotti Chimici
5 of 6 patients had 0 bleeds requiring Factor VIII infusions after Factor VIII levels were above 5%.. Efficacy Data on 6e13 vg/kg Dose as Announced at ISTH July 11, 2017 As of the May 31, 2017 data cutoff, all seven patients at the 6e13 vg/kg dose had reached 52 weeks of post-treatment follow-up. Median and mean Factor VIII levels from week 20 through 52 for the 6e13 vg/kg dose cohort have been consistently within the normal levels post treatment, expressed as a percentage of normal factor activity in blood. (See Press Release). At one year after dosing, the median and mean Factor VIII levels of the 6e13 vg/kg cohort continue to be above 50%. After 52 weeks of follow-up, the phase 1/2 study protocol specifies that planned patient visits are reduced in frequency from once a week to once every twelve weeks. Consequently, as of May 31, 2017 when all patients in the 6e13 vg/kg dose had reached 52 weeks of follow up, all patients in the 6e13 vg/kg dose converted to a quarterly follow-up visit ...
The 50:50 mix is a test used to identify if the patient has a deficiency in a factor versus an inhibitor. It entails mixing a sample of patient with normal plasma. Full correction in the PTT indicates a factor deficiency. A lack of correction indicates an inhibitor.. If the inhibitor is present, it is important to rule out a lupus anticoagulant. Typically a dilute Russells viper venom time (dRVVT) is used for confirmation.. ...
Synonyms for Coagulation factors in Free Thesaurus. Antonyms for Coagulation factors. 2 synonyms for coagulation: clotting, curdling. What are synonyms for Coagulation factors?
Eventbrite - Canadian Neurovascular Health Society presents Conference Draw #1: Blood Analysis (Sonoclot) - Wednesday, September 26, 2012 at Foothills Centennial Center, Okotoks, Alberta. Find event and ticket information.
Liquid reagent, ready to use, for the determination of Activated Partial Thromboplastin Time (APTT) on citrated human plasma, using a manual, semi automated or automated clotting method. Low sensitivity to Lupus Anticoagulant.
Global Blood Coagulation Testing Market Information by instruments (prothrombin time, APTT, thrombo test) by methods (Global test, Local test) by End Users (Hospitals, clinics, Research Institutes) - Forecast to 2027
Disseminated intravascular coagulation and Streptococcal pneumonia with sepsis. Patient presented with symptoms of pneumonia and developed rapid sepsis and respiratory failure requiring intubation.
Learn more about Disseminated Intravascular Coagulation at Medical City Dallas DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
There is a large amount of experimental evidence that supports the concept of an association between blood coagulation and malignant disease. Since several chapters within this volume describe...
One of the most memorable discussions regarding the cost of care was at 4:45AM during surgical morning rounds. As usual, the interns would present the overnight events of their patients to the chief resident and a plan for the day would be agreed upon. These morning rounds were particularly intense: in addition to the 30 patients that an intern had to manage solo over night, the brutal hours that the surgical oncology service demanded, our chief resident, Dr. W., was a former army officer and his team was therefore ran in the most organized fashion that one could hope for. On the first morning, as the interns were plowing through test results from laboratory data, Dr. W. asked them to justify some of the lab tests. "Why did we order a Calcium on Mr. Z.? ", "Why do are we getting daily coagulation studies on Ms. S.?". Everyone seemed puzzled, as this was the first time when they were confronted with this issue. Doing daily blood draws is considered as much of a routine as feeding patients and it ...
... Reagents are stable until the expiry date shown on the label when stored tightly closed and ifcontaminations are prevented
This report presents a comprehensive analysis of the German coagulation market, including:Major issues pertaining to the German coagulation laboratory
A prothrombin time test measures how long it takes for your blood plasma to clot. Prothrombin, or factor II, is one of 12 proteins in the clotting process ...
Get exceptional Coagulation analyzer services from highly experienced & loving pet care professionals in Dallas, TX. Visit Animal Diagnostic Clinic today.
Bleeding diathesis is basically an abnormal bleeding condition which in most cases is caused by hypocoagulability, a condition caused when the bodys coagulation system becomes faulty.
An evaluation of the Lancer Coagulyzer in the measurement of the one-stage prothrombin time.: An evaluation of a photoelectric clot timer, the Lancer Coagulyzer
Looking for online definition of factor VIII activity in the Medical Dictionary? factor VIII activity explanation free. What is factor VIII activity? Meaning of factor VIII activity medical term. What does factor VIII activity mean?
Coagulation and fibrinolytic studies were performed in 30 subarachnoid hemorrhage patients and 30 age-matched and sex-matched controls.. Systemic abnormalities were detected in the following tests: recalcification time, fibrinogen, partial thromboplastin time, K value of thromboelastogram and euglobulin lysis time.. The data suggest that subarachnoid hemorrhage patients with fibrinogen values over 400 mg% have a low probability of survival.. Test abnormalities probably reflect tissue damage and/or meningeal reaction to the subarachnoid hemorrhage. Similar abnormalities can be noted in patients with cerebral trauma and in some patients with nonhemorrhagic cerebrovascular disease.1. Our data reveal that subarachnoid hemorrhage patients may exhibit simultaneously evidence suggesting increased coagulability and activation of fibrinolytic mechanisms. Under these circumstances administration of agents to suppress lytic activity might lead to disastrous consequences such as widespread intervascular ...
Activated partial thromboplastin times (APTT) for monitoring heparin therapy for venous thromboembolism tended to be inappropriately short if blood was collected in commercially available evacuated glass tubes. Five types of evacuated tubes marketed under the trade names Vacutainer and Venoject were examined. The APTT of heparinized blood collected in these tubes correlated poorly (r = 0.04 to 4 = 0.25) with that of blood samples from the same patients collected in plastic tubes. Most of the evacuated tube APTT were shorter than that of blood collected in plastic or siliconised glass tubes, but the results were unpredictable and varied from tube to tube and from batch to batch. This effect on heparin is apparently due to an unidentified substances which is eluted from the rubber stoppers of the tubes. Heparin control according to the APTT blood collected in these evacuated tubes is hazardous.. ...
Thromboelastography (TEG) is a method of testing the efficiency of blood coagulation. It is a test mainly used in surgery and anesthesiology, although few centers are capable of performing it. More common tests of blood coagulation include prothrombin time (PT,INR) and partial thromboplastin time (aPTT) which measure coagulation factor function, but TEG also can assess platelet function, clot strength, and fibrinolysis which these other tests cannot. Thromboelastometry (TEM), previously named rotational thromboelastography (ROTEG) or rotational thromboelastometry (ROTEM), is another version of TEG in which it is the sensor shaft, rather than the cup, that rotates. A small sample of blood is taken from the selected person and rotated gently through 4º 45, six times a minute, to imitate sluggish venous flow and activate coagulation. A thin wire probe is used to measure, which the clot forms around. The speed and strength of clot formation is measured in various ways, typically by computer. The ...
The Coagulation Panel is a common set of labs ordered to monitor a patients bleeding status. Lab values are commonly presented in a 3-way diagram, colloquially known as the Mercedes diagram. The top left value is the Prothrombin Time (PT). This lab value evaluates the extrinsic pathway and common pathways of coagulation. PT is primarily affected by the following coagulation factors: I (1), II (2), V (5), VII (7), and X (10). The top right value is the Partial Thromboplastin Time (PTT), sometimes called the activated partial thromboplastin time (aPTT). This lab value evaluates the intrinsic pathway and common pathways of coagulation. PTT is primarily affected by the following coagulation factors: VIII (8), IX (9), XI (11), and XII (12). The bottom value is the International Normalized Ratio (INR). The INR is a ratio calculated from a patients PT value, by dividing it by a normal PT value, or population mean. INR is primarily used in patients taking warfarin (Coumadin), to monitor therapeutic
0070] In this case, the analyzing section 42 determines whether or not the aggregability of the platelets is good depending on whether the shortening width (or delay width) Δt of the blood coagulation time of the sample blood to which the platelet activating agent etc. is added is larger or smaller than the reference value (Δts). Specifically, the analyzing section 42 determines that the aggregability of the platelets is high if the shortening width Δt of the blood coagulation time of the sample blood to which the platelet activating agent is added is larger than the reference value (Δts). Conversely, the analyzing section 42 determines that the aggregability of the platelets is low if the shortening width Δt is smaller than the reference value (Δts). Alternatively, the analyzing section 42 determines that the aggregability of the platelets is high if the delay width Δt of the blood coagulation time of the sample blood to which the platelet inactivating agent is added is larger than the ...
Factor V is a large (330 kilodalton) single-chain nonenzymatic cofactor that is synthesized in hepatocytes, megakaryocytes, and endothelial cells.6,7,9 Approximately 20% of the total factor V is carried in the α granules of platelets and is released when platelets are activated.6 The structure of factor V is similar to that of factor VIII.9 Factor Vs plasma concentration is 7 mg/mL and half-life is about 15 to 36 hours. Factor V activation occurs by both the extrinsic and intrinsic pathways. Factor V deficiency should be considered when a patient with bleeding history has both extended protime (PT) and activated partial thromboplastin time (aPTT). Congenital factor V deficiency, sometimes referred to as parahemophilia, is rare (less than one case per million individuals) and is inherited as an autosomal recessive trait.6,7,9 This condition affects both males and females and the prevalence of inherited factor V deficiency is equal in all ethnic groups.9 Factor V levels are decreased both in ...
The trauma field is aflutter with research and practice changes involving trauma-induced coagulopathy (TIC), the biochemical response to injury, also known as acute traumatic coagulopathy and acute coagulopathy of trauma-shock. Discoveries are still being made in this revitalized area of investigation, and old notions about the coagulation process are being sidelined, along with traditional measures of coagulation. The upshot for laboratorians is, if viscoelastic tests such as thromboelastography (TEG) and thromboelastometry (ROTEM), are not already part of your coagulation testing armamentarium, chances are they soon will be.
Activated partial thromboplastin clotting time (aPTT) is one of a handful of diagnostic coagulation tests that provides a measurement for the length of time it takes an individuals blood to form a clot. Blood clotting factors come together in a cascade process when a blood vessel is damaged to form a blood clot and stop bleeding. Clotting factors XII, IX, II, X, XI, VIII, V, fibrinogen, prekallikrein, and high-molecular-weight kininogen are components that make up the intrinsic clotting pathway and the common final pathway. These factors are measured in the aPTT test. The partial thromboplastin time test is performed before the activated partial thromboplastin time. The difference between these two tests is a special activation solution is added to the sample for the aPTT that increases the clotting time to provide a smaller reference range. If both the PTT and aPTT tests yield abnormal results, it is suggested the patient has a deficiency of factor I, V, X, or II. A normal PTT with an abnormal ...
The acquired inhibitors of coagulation have been observed in very rare cases of monoclonal gammopathies. We report a very rare case of anti-factor XI antibodies in patient with plasma cell leukemia (PCL). This is a 59-year-old male patient without pathological history, admitted to the nephrology department for management of renal insufficiency and anemia syndrome. The history and physical examination revealed stigmata of hemorrhagic syndrome including hemothorax and hemoptysis. The hemostasis assessment showed an isolated prolonged activated partial thromboplastin time (APTT) with APTT ratio = 2.0.The index of circulating anticoagulant (37.2%) revealed the presence of circulating anticoagulants. The normalized dilute Russell viper venom time ratio of 0.99 has highlighted the absence of lupus anticoagulants. The coagulation factors assay objectified the decrease of the factor XI activity corrected by the addition of the control plasma confirming the presence of anti-factor XI autoantibodies. In addition,
Reversal of anticoagulation can be needed in patients undergoing heart valve surgery. ROTEM® has been correlated with international normalized ratio (INR) in patients on warfarin but not with patients on acenocoumarol. This study investigates the reliability of ROTEM® for detecting INR values below the 1.5 threshold in patients on acenocoumarol therapy. Patients on oral anticoagulation with acenocoumarol after elective heart valve replacement were prospectively included in the study. INR and the ROTEM® were measured simultaneously. ROTEM® parameters included coagulation time, clot formation time, alpha angle, and maximal clot firmness after tissue factor activation (EXTEM). Concordance between INR and ROTEM® was analyzed by Lins concordance coefficient (LCC) and the correlation with Spearmans rho. Fifty-four consecutive patients (40 female; median age 67years) were included. Clotting time (CT) was the parameter that best correlated with INR (r=0.81, ...
TY - JOUR. T1 - Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. AU - Park, Myung S.. AU - Martini, Wenjun Z.. AU - Dubick, Michael A.. AU - Salinas, Jose. AU - Butenas, Saulius. AU - Kheirabadi, Bijan S.. AU - Pusateri, Anthony E.. AU - Vos, Jeffrey A.. AU - Guymon, Charles H.. AU - Wolf, Steven. AU - Mann, Kenneth G.. AU - Holcomb, John B.. PY - 2009/8/1. Y1 - 2009/8/1. N2 - OBJECTIVES: To investigate the hemostatic status of critically ill, nonbleeding trauma patients. We hypothesized that a hypercoagulable state exists in patients early after severe injury and that the pattern of clotting and fibrinolysis are similar between burned and nonburn trauma patients. MATERIALS: Patients admitted to the surgical or burn intensive care unit within 24 hours after injury were enrolled. Blood samples were drawn on days 0 through 7. Laboratory tests included prothrombin time (PT), activated partial ...
Lupus anticoagulants prolong clotting times in phospholipid-dependent coagulation tests. Lupus Ratio assays are integrated tests for lupus anticoagulants that may be based on APTT, RVVT or dPT clotting times. If a patient is being treated with unfractionated heparin, however, the heparin prolong clotting times and the diagnosis of lupus anticoagulant is invalidated. Commercial assays may have heparin neutralising agents added to their reagents. However, the type and efficacy of the heparin neutralisation is often not documented. We wanted to test the influence and efficacy of heparin neutralisers in the Lupus Ratio assay. Several heparin neutralisers were tested, and polybrene was chosen for further testing. Unfractionated heparin and/or polybrene were added to normal plasma and to plasma from patients with or without lupus anticoagulant and clotting times compared before and after the additions. Lupus anticoagulant-positive patients were given 5000 IU i.v. of unfractionated heparin and plasma was

China Disposable Medical ESR Blood Collection Tube - China ESR Tube EDTA Tube, Vacuum Blood Collection TubeChina Disposable Medical ESR Blood Collection Tube - China ESR Tube EDTA Tube, Vacuum Blood Collection Tube

Vacuum Blood Collection Tube from Disposable Medical ESR Blood Collection Tube - Qingdao Carong Import & Export Co., Ltd. ... China Disposable Medical ESR Blood Collection Tube, Find details about China ESR Tube EDTA Tube, ... coagulation or blood blister and influence the test result.. 3. The tube can match with a variety of erythrocyte ... ESR Tube EDTA Tube, Vacuum Blood Collection Tube, Vacuum Blood Test Tube manufacturer / supplier in China, offering Disposable ...
more infohttp://carong.en.made-in-china.com/product/aXJnuFWMOxUb/China-Disposable-Medical-ESR-Blood-Collection-Tube.html

GPM.3.3.2.0002.15 Human coagulation factor VII   | Pharmacopoeia.ruGPM.3.3.2.0002.15 Human coagulation factor VII | Pharmacopoeia.ru

GPM.3.3.2.0002.15 Human coagulation factor VII Pharmacopoeia Monograph First Edition The present Pharmacopoeia Monograph ... "Determination of blood coagulation factor activity".. Thrombin. Thrombin should be absent. The test is carried out by ... "Determination of blood coagulation factor activity".. Human coagulation factor VII activity. Not less than 15 IU per millilitre ... "Determination of blood coagulation factor activity" (the test for the absence of thrombin). ...
more infohttp://pharmacopoeia.ru/en/fs-3-3-2-0002-15-faktor-svertyvaniya-krovi-vii-cheloveka/

WO2005106467A1 - Blood coagulation test cartridge, system, and method 
        - Google PatentsWO2005106467A1 - Blood coagulation test cartridge, system, and method - Google Patents

... of a blood test sample deposited in a test cartridge is disclosed. A cartridge housing having upper and lower major sides and a ... Resistance to agitator movement due to coagulation is detected, and the coagulation time is measured. ... chamber having a test chamber pivot element and is provided with a cartridge port for introducing a test sample into the test ... through the test sample in the absence of coagulation. A timer is started when the agitator movement is commenced whereupon the ...
more infohttps://patents.google.com/patent/WO2005106467A1/en

Global Blood Coagulation Testing Market Growth Opportunities, Key Driven Factors, Market Scenario FoGlobal Blood Coagulation Testing Market Growth Opportunities, Key Driven Factors, Market Scenario Fo

... thrombo test) by methods (Global test, Local test) by End Users (Hospitals, clinics, Research Institutes) - Forecast to 2027 ... Global Blood Coagulation Testing Market Information by instruments (prothrombin time, APTT, ... Pune, Maharashtra -- (SBWIRE) -- 01/25/2017 -- Market Synopsis of Blood Coagulation Testing Market:. Blood Coagulation Testing ... Global Blood Coagulation Testing Market Information by instruments (prothrombin time, APTT, thrombo test) by methods (Global ...
more infohttp://www.sbwire.com/press-releases/global-blood-coagulation-testing-market-growth-opportunities-key-driven-factors-market-scenario-forecast-to-2027-764331.htm

The blood coagulation tests from ischemic stroke patients with or without type 2 diabetes mellitus | AbstractThe blood coagulation tests from ischemic stroke patients with or without type 2 diabetes mellitus | Abstract

We determined the plasma protein C and coagulation factor X activities, prothrombin, fibrinogen and soluble fibrin monomer ... The blood coagulation tests from ischemic stroke patients with or without type 2 diabetes mellitus. Objective: We determined ... haemostatic screening coagulation time tests with coagulation analyzer, glucose and glycosylated hemoglobin content and BMI ( ... content and performed the haemostatic screening coagulation time tests under acute ischemic stroke patients with or without ...
more infohttps://www.alliedacademies.org/abstract/the-blood-coagulation-tests-from-ischemic-stroke-patients-with-or-without-type-2-diabetes-mellitus-10629.html

Patent US3814585 - Method and apparatus for testing blood coagulation - Google PatentsPatent US3814585 - Method and apparatus for testing blood coagulation - Google Patents

6. Apparatus for testing blood coagulation comprising in combination: (a) a container for holding a blood sample; (b) an ... A still further, and more general object, is to provide novel and improved blood coagulation test methods which may be ... The common property of materials most suitable for contact with the blood sample in coagulation testing thus appears to be ... BACKGROUND OF THE INVENTION The present invention relates to the testing of blood coagulation or clotting time and, more ...
more infohttp://www.google.com/patents/US3814585?dq=7,177,838

Coagulation Blood Tests | Walk-In LabCoagulation Blood Tests | Walk-In Lab

Plus, shop additional Blood Disorder Tests confidentially without insurance or a doctors note. ... Order from our Coagulation blood tests and panels selection. ... D-Dimer Blood Test. A D-Dimer Blood Test rules out deep vein ... the D-Dimer Blood Test, and the Fibrinogen Activity Blood Test. Thank you for browsing our selection of Coagulation blood tests ... Vitamin K1 Blood Test. This Vitamin K1 Test measures Vitamin K1, the natural form of vitamin K, levels in the blood. ...
more infohttps://www.walkinlab.com/categories/view/blood-disorder-tests/coagulation

Coagulation Factors Blood TestCoagulation Factors Blood Test

... on why the laboratory test is performed, specimen collected, the significance of the results, and its use in diagnosing medical ... Learn in-depth information on Coagulation Factors Blood Test, ... Factor Assays Blood Test. What is Coagulation Factors Blood ... What is the Significance of the Coagulation Factors Blood Test Result?. The significance of Coagulation Factors Blood Test ... The Coagulation Factors Blood Tests are tests to help assess the activity and levels of 9 coagulation factors (though there are ...
more infohttps://www.dovemed.com/common-procedures/procedures-laboratory/coagulation-factors-blood-test/

Impact of different storage times at room temperature of unspun citrated blood samples on routine coagulation tests results....Impact of different storage times at room temperature of unspun citrated blood samples on routine coagulation tests results....

Impact of different storage times at room temperature of unspun citrated blood samples on routine coagulation tests results. ...
more infohttps://insights.ovid.com/pubmed?PMID=28481034

Germany Diagnostics Market Shares and Segment Forecasts for 300 Tests: Blood Banking, Cancer, Coagulation, Clinical Chemistry,...Germany Diagnostics Market Shares and Segment Forecasts for 300 Tests: Blood Banking, Cancer, Coagulation, Clinical Chemistry,...

This new report provides an overview of the German diagnostic testing market, including sales and market shares of leading ... reagent and instrument suppliers, as well as test volume and sales. ... Coagulation Testing Market. Coagulation Test Volume Forecasts by Market Segment. Coagulation Reagent Sales Forecasts by Market ... Market Shares of Major Suppliers of Coagulation Diagnostic Products. Blood Banking Market. Blood Typing and Grouping Test ...
more infohttps://www.aarkstore.com/healthcare/1657833/germany-diagnostics-market-shares-and-segment-forecasts-and-growth-strategies-for-suppliers

Basic Skills in Interpreting Laboratory Data - Google BooksBasic Skills in Interpreting Laboratory Data - Google Books

It provides fundamentals of interpreting lab test results not only for pharmacy students, but also for practitioners as an aid ... and pharmacogenomics and laboratory tests.Mini-cases embedded in each chapter provide therapy-related examples and reinforce ... 4th Edition is a case-based learning tool that will enhance your skills in clinical lab test interpretation. ... abnormal acid acidosis activity acute adults albumin anemia antibiotic antibody antigen assay assess bacteria bilirubin blood ...
more infohttps://books.google.com/books/about/Basic_Skills_in_Interpreting_Laboratory.html?id=AUSIRcV_as0C&hl=en

First-line Therapy with Coagulation Factor Concentrates Combined with Point-of-Care Coagulation Testing Is Associated with...First-line Therapy with Coagulation Factor Concentrates Combined with Point-of-Care Coagulation Testing Is Associated with...

Signature Whole Blood Coagulation System; International Technidyne Corp., Edison, NJ). This test is activated by silicium, ... Coagulation Factor Concentrates Combined with Point-of-Care Coagulation Testing Is Associated with Decreased Allogeneic Blood ... Coagulation Factor Concentrates Combined with Point-of-Care Coagulation Testing Is Associated with Decreased Allogeneic Blood ... Coagulation Factor Concentrates Combined with Point-of-Care Coagulation Testing Is Associated with Decreased Allogeneic Blood ...
more infohttp://anesthesiology.pubs.asahq.org/article.aspx?articleid=1933929

Estonia Diagnostics Market Forecasts for 500 Tests: Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs...Estonia Diagnostics Market Forecasts for 500 Tests: Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs...

Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow ... ... Blood Banking Market. Table 1: Blood Bank Test Volume and Reagent Sales Forecast by Test Category. Table 2: Blood Typing and ... Coagulation Testing Market. Table 23: Coagulation Test Volume Forecast by Procedure. Table 24: Coagulation Diagnostics Market ... Estonia Diagnostics Market Forecasts for 500 Tests: Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs ...
more infohttps://www.reportlinker.com/p05825073/Estonia-Diagnostics-Market-Forecasts-for-500-Tests-Blood-Banking-Cancer-Diagnostics-Clinical-Chemistry-Coagulation-Drugs-of-Abuse-Endocrine-Function-Flow-Cytometry-Hematology-Immunoproteins-Infectious-Diseases-Molecular-Diagnostics-TDM.html

Crinone 8 % Gel - Uses, Dosage, Side Effects, Price, Composition | PractoCrinone 8 % Gel - Uses, Dosage, Side Effects, Price, Composition | Practo

Blood coagulation tests. Report the use of progesterone to the doctor before undergoing a test to measure the coagulation time ... Heart and blood vessel disorder. This medicine is not recommended for use in patients having an active or historic instance of ... Blood clotting disorders. Use of this medicine is not recommended for patients having a clotting disorder. It is advised to ... Use of this medicine can sometimes cause a loss of vision by blocking the flow of blood from the retina to the heart. Hence ...
more infohttps://www.practo.com/medicine-info/crinone-8-gel-3270

Nance 100 MG Injection - Uses, Dosage, Side Effects, Price, Composition | PractoNance 100 MG Injection - Uses, Dosage, Side Effects, Price, Composition | Practo

Blood coagulation tests. Report the use of progesterone to the doctor before undergoing a test to measure the coagulation time ... Heart and blood vessel disorder. This medicine is not recommended for use in patients having an active or historic instance of ... Blood clotting disorders. Use of this medicine is not recommended for patients having a clotting disorder. It is advised to ... Use of this medicine can sometimes cause a loss of vision by blocking the flow of blood from the retina to the heart. Hence ...
more infohttps://www.practo.com/medicine-info/nance-100-mg-injection-6896

Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assaysEffects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays

analysis; anticogaulants; apixaban; blood coagulation tests; factorXa National Category Clinical Medicine Identifiers. URN: urn ... Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. Hillarp, A. ... To investigate the effects of apixaban on commonly used coagulation methods, and to evaluate anti-FXa assays for specific ... Laboratory monitoring is not necessary, but the effects on common coagulation reagents and assays constitute clinically ...
more infohttp://www.diva-portal.org/smash/record.jsf?pid=diva2:757216

Patent US6793660 - Threaded syringe for delivery of a bone substitute material - Google PatentsPatent US6793660 - Threaded syringe for delivery of a bone substitute material - Google Patents

Blood coagulation test system. US5472424. Apr 5, 1994. Dec 5, 1995. Merit Medical Systems, Inc.. Syringe with volume ...
more infohttp://www.google.com/patents/US6793660?dq=inassignee:doubleclick

Italy Diagnostics Market Shares and Segment Forecasts for 300 Tests 2017-2021: Blood Banking, Cancer, Coagulation, Clinical...Italy Diagnostics Market Shares and Segment Forecasts for 300 Tests 2017-2021: Blood Banking, Cancer, Coagulation, Clinical...

Blood Banking, Cancer, Coagulation, Clinical Chemistry, Flow Cytometry, Hematology, Immunodiagnostics, Infectious Diseases, ... 57 Pages Report] Check for Discount on Italy Diagnostics Market Shares and Segment Forecasts for 300 Tests 2017-2021: ... Coagulation Testing Market. Coagulation Test Volume Forecasts by Market Segment. Coagulation Reagent Sales Forecasts by Market ... Market Shares of Major Suppliers of Coagulation Diagnostic Products. Blood Banking Market. Blood Typing and Grouping Test ...
more infohttp://www.reportsnreports.com/reports/1281408-italy-diagnostics-market-shares-and-segment-forecasts-for-300-tests-2017-2021-blood-banking-cancer-coagulation-clinical-chemistry-flow-cytometry-hematology-immunodiagnostics-infectious-diseases-microbiology-suppliers.html

Tromboelastografia em pacientes estáveis em diálise peritoneal automatizadaTromboelastografia em pacientes estáveis em diálise peritoneal automatizada

Blood coagulation disorders. Blood coagulation tests. Chronic renal insufficiency. Fibrinogen. Hemostasis. Serum albumin. ... Thromboelastography (TEG) is a method that evaluate blood properties through coagulations global and dynamic perspectives, ... Finally it classifies the coagulation in normal, hypocoagulant or hypercoagulant according to the coagulation index (CI), so ... 9.3±1.5 K; p= p=0.000); altered too in 78% and 33%, respectively, in normal coagulation patients. Hypercoagulant patients ...
more infohttp://www.teses.usp.br/teses/disponiveis/5/5148/tde-23042018-134702/pt-br.php

Elevated cardiac troponin I in sepsis and septic shock: no evidence for thrombus associated myocardial necrosis.Elevated cardiac troponin I in sepsis and septic shock: no evidence for thrombus associated myocardial necrosis.

Blood Coagulation Tests. Female. Humans. Male. Middle Aged. Myocardium / pathology. Necrosis. Sepsis / blood*. Shock, Septic / ... blood*. Systemic Inflammatory Response Syndrome / blood. Thrombelastography. Thrombosis / blood. Troponin I / blood*. ... As the coagulation status assessed with thrombelastometry is performed in whole blood, this technique seems to mirror the ... Year: 1981Comparison of thrombelastography with common coagulation tests.Thromb Haemost467527567330829. 23. Gonano C,Sitzwohl C ...
more infohttp://www.biomedsearch.com/nih/Elevated-Cardiac-Troponin-in-Sepsis/20140242.html

NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth | OncogeneNGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth | Oncogene

Here we took advantage of the unique coagulation properties of staphylocoagulase and genetically engineered it to generate a ... Blood clotting test. Blood coagulation tests were performed as previously described [14, 44]. Briefly, 1% sodium citrate was ... blood from three mice per group was collected to test serum levels of blood chemical markers for organ function. After 24 h, ... The presence of blood coagulation was documented at various time points by leaning the tubes at 45° angles. ...
more infohttps://www.nature.com/articles/s41388-018-0213-4?error=cookies_not_supported&code=37c1b517-6c57-4ea9-9e37-94643a853616

Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review...Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review...

Blood coagulation tests were normal. The direct antiglobulin test was negative. Hepatitis screening for the hepatitis B virus ( ... Blood testing showed anemia (Hemoglobin [Hb] 8.8 g/dL) with an increase of hemolysis indices: reticulocytosis was 119×109/L ( ... Because of a clinical deterioration and no response to intravenous human immunoglobulin therapy, a peripheral blood smear was ... Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura Blood. ...
more infohttp://www.haematologica.org/content/103/3/e138

Minimally Invasive Surgery: Using Natural Orfices - Full Text View - ClinicalTrials.govMinimally Invasive Surgery: Using Natural Orfices - Full Text View - ClinicalTrials.gov

Patients on blood thinners or aspirin or abnormal blood coagulation tests. Inclusion criteria for transvaginal cholecystectomy: ...
more infohttps://clinicaltrials.gov/ct2/show/NCT00530998?recr=Open&cond=%22Cholelithiasis%22&rank=2

Minimally Invasive Surgery: Using Natural Orfices - Full Text View - ClinicalTrials.govMinimally Invasive Surgery: Using Natural Orfices - Full Text View - ClinicalTrials.gov

Patients on blood thinners or aspirin or abnormal blood coagulation tests. Inclusion criteria for transvaginal cholecystectomy: ...
more infohttps://clinicaltrials.gov/ct2/show/study/NCT00530998?view=record
  • A PPT Test is useful in detecting deficiencies or inhibitors to the intrinsic (Factors VIII, IX, XI, and XII) and common (Factors II, V, X, and fibrinogen) pathway coagulation factors. (walkinlab.com)
  • Based on a 5-yr experience in POC-supported coagulation management in liver transplantation 19 - 20 we developed and implemented an algorithm including POC-supported coagulation management in cardiovascular surgery, based on first-line therapy with specific coagulation factor concentrates, such as fibrinogen concentrate and prothrombin complex concentrate (PCC), combined with point-of-care thromboelastometry and impedance aggregometry. (asahq.org)
  • The effect of alfalfa on coagulation system was exerted via increasing the blood level of fibrinogen and it had no effect on other indices. (ac.ir)
  • While earlier in the clinical laboratory, the concentration example, the components of the blood was determined almost exclusively by means of liquid reagents, have gained in recent years, so-called carrier-bound tests in importance. (google.com)
  • In these the reagents in appropriate layers of a solid test carrier are embedded, to which a drop of sample is applied. (google.com)
  • The test is started by adding appropriate reagents. (wikipedia.org)
  • Among ischemic stroke patients with type 2 diabetes mellitus the differences were more significant for all Time tests of the coagulation cascade, but deviations of haemostatic biochemical markers were more pronounced in ischemic stroke patients without diabetes mellitus. (alliedacademies.org)
  • The results of the present study showed that use of the extract decreased significantly the serum levels of ALP, ALT, and also blood glucose concentration in the experimental groups, compared to the control group. (ac.ir)
  • Ferromagnetic agitator vane leaflets extend from an agitator pivot element supported by the test chamber pivot element intermediate the upper and lower major sides for rotational motion. (google.com)
  • CONCLUSIONS/SIGNIFICANCE: We found no differences in coagulation parameters analyzed with rotational thrombelastometry between cTnI-positive and -negative patients with SIRS, severe sepsis, and septic shock. (biomedsearch.com)
  • Platelet count test is performed by two major techniques (light scattering, electronic aperture-impedance counting) to distinguish between platelets, leucocytes and erythrocytes. (wordpress.com)
  • TRANFUSION of packed red blood cells (PRBC), fresh frozen plasma (FFP), cryoprecipitate, and platelet concentrates is strongly associated with increased morbidity and mortality in cardiovascular surgery, patients with myocardial infarction, and critically ill patients. (asahq.org)
  • Patients with many different cardiovascular diseases have a higher likelihood of experiencing a blood clot or loss of blood flow in border-zone regions of the brain. (wikipedia.org)
  • The invention relates to a test carrier for the analytical Bestim mung a component of a body fluid with a base layer and at least two flat in the initial state of the test carrier prior to making a determination on separate, but mutually by external manipulation can be brought into contact test layers. (google.com)
  • This Factor V Leiden Mutation Analysis Blood Test is used to detect Leiden (R506Q) mutation in factor V gene (OMIM 227400), causing an increased risk of thrombosis. (walkinlab.com)
  • This test helps determine if the patient is taking in high dose of warfarin which may put them at risk of serious bleeding and if the dose is too little they are at risk of thrombosis. (wordpress.com)
  • The protein C activity was found to be significantly decreased in blood of patients with ischemic stroke with and without diabetes. (alliedacademies.org)
  • Here we took advantage of the unique coagulation properties of staphylocoagulase and genetically engineered it to generate a new fusion protein with novel anti-cancer properties. (nature.com)
  • Since 1997, studies have described the use of a truncated form of the human coagulation-inducing protein tissue factor (tTF) conjugated to diverse tumor endothelial moieties such as NGR (Asn-Gly-Arg) peptides. (nature.com)
  • A mathematical formula determined by the manufacturer can be used to determine a Coagulation Index (CI) (or overall assessment of coagulability) which takes into account the relative contribution of each of these 4 values into 1 equation.The G-value is a log-derivation of the MA and is meant to also represent the clot strength using dynes/sec as its units. (wikipedia.org)
  • 14 - 18 However, these studies vary widely with respect to the scope of POC measurements performed, availability and use of coagulation factor concentrates, and by consideration of either the intraoperative or postoperative period. (asahq.org)
  • I can tell you that the pre-screening we have gone through was extensive, and includes blood testing before the procedure. (thisisms.com)
  • in fact we were instructed to wait until we were within 30 days of the procedure to have the blood work done. (thisisms.com)
  • Watershed strokes are caused by ischemia or a lack of blood flow to the brain. (wikipedia.org)
  • The agitator vane leaflets can be swept, in response to an external magnetic field, through the test sample in the absence of coagulation. (google.com)
  • Global Blood Coagulation Testing market has been segmented On the basis of by instruments, by methods, by end users. (sbwire.com)
  • A still further, and more general object, is to provide novel and improved blood coagulation test methods which may be implemented in a simple and eflicient manner with relatively inexpensive and reliable equipment. (google.com)
  • To date no data regarding coagulation disturbances as a possible mechanism for cTnI release during sepsis are available. (biomedsearch.com)
  • BACKGROUND OF THE INVENTION Blood coagulation is a complex chemical and physical reaction that occurs when blood (herein, 'blood' shall mean whole blood, citrated blood, platelet concentrate, plasma, or control mixtures of plasma and blood cells, unless otherwise specifically called out, and may include heparinized blood) comes into contact with an activating agent, such as an activating surface or an activating agent. (google.com)
  • Some of the key players in the global coagulation testing market include Alere Inc., Hoffmann-La Roche AG, Sysmex Corporation, Abbott, Siemens AG, Axis-Shield Diagnostics Ltd., Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company and others. (wordpress.com)
  • Added to the above, the technological advancements in coagulation testing devices such as the modern coagulometers are significantly drive the global demand for coagulation testing market. (wordpress.com)
  • This combined phase 1/2a clinical trial is to investigate the safety, dose limiting toxicity (DLT), and exploratory efficacy of three repeated intraventricular administrations of NEUROSTEM® (human umbilical cord blood-derived mesenchymal stem cells) versus placebo via an Ommaya reservoir at 4 week intervals in patients with Alzheimer's disease. (clinicaltrials.gov)
  • Accordingly, it is a principal object of the present invention to provide a method and apparatus for in vitro testing of blood coagulation which has a much higher degree of repeatability and accuracy than prior techniques while remaining fast and simple in implementation. (google.com)
  • Smaller studies suggest that implementation of point-of-care (POC) coagulation tests coupled to algorithm-based management decreases transfusion requirements in cardiac surgery. (asahq.org)
  • The thread may be inserted through the needle of the syringe and an electric motor with suitable reduction gearing used to draw the thread through the needle and blood sample within the syringe at an ap propriate speed, e.g., a few millimeters per minute. (google.com)